Cannabidiol (CBD) shows promise in regulating appetite, glucose and lipid metabolism, and inflammation in preclinical models ...

GlyphAgo is an oral prodrug of agomelatine, a medicine with established clinical efficacy in four out of four previous third-party randomized, placebo-controlled studies in generalized anxiety ...

GlyphAgo is designed to overcome a key limitation of agomelatine by shifting absorption toward the intestinal lymphatics, avoiding first-pass liver metabolism, and increasing systemic exposure of the ...